Cargando…
Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma
Despite great advancements in the treatment of non-Hodgkin lymphoma (NHL), sensitivity of different subtypes to therapy varies. Targeting the aberrant activation NF-κB signaling pathways in lymphoid malignancies is a promising strategy. Here, we report that 11(13)-dehydroivaxillin (DHI), a natural c...
Autores principales: | Xiao, Xinhua, Li, Huiliang, Jin, Huizi, Jin, Jin, Yu, Miao, Ma, Chunmin, Tong, Yin, Zhou, Li, Lei, Hu, Xu, Hanzhang, Zhang, Weidong, Liu, Wei, Wu, Yingli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636986/ https://www.ncbi.nlm.nih.gov/pubmed/28906487 http://dx.doi.org/10.1038/cddis.2017.442 |
Ejemplares similares
-
Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
por: Grover, Natalie S., et al.
Publicado: (2015) -
New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017) -
Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022) -
The relationship between consumption of nitrite or nitrate and risk of non-Hodgkin lymphoma
por: Yu, Mengxia, et al.
Publicado: (2020) -
Effects of chemotherapeutic agent bendamustine for non-hodgkin lymphoma on spermatogenesis in mice
por: Zang, Min-bo, et al.
Publicado: (2018)